Allarity Therapeutics, Inc.
ALLR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001860657
No open-market purchases or sales by Allarity Therapeutics, Inc. insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $1.65M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Allarity Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 4 | 7 | +3 |
| Shares | 5.08K | 690.6K | +685.5K (+13,486.3%) |
| Value | $33.3K | $515.6K | +$482.3K (+1,446.7%) |
New holders (5)
Institutions that held Allarity Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sabby Management, LLC | 359,400 | $268.5K | 0.85% |
| Armistice Capital, LLC | 261,000 | $195.0K | 0.01% |
| Citadel Advisors LLC | 26,215 | $19.6K | 0.00% |
| Virtu Financial LLC | 25,795 | $19.0K | 0.00% |
| Two Sigma Securities, LLC | 12,587 | $9.40K | 0.00% |
Sold out (2)
Institutions that held Allarity Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| UBS Group AG | 3,617 | $23.9K |
| Acadian Asset Management LLC | 32 | $0 |